Immatics N.V. has announced updated Phase 1a dose escalation data from its ongoing clinical trial of IMA203CD8, a second-generation PRAME-targeting cell therapy, in heavily pre-treated patients with solid tumors. The interim results, which were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025, indicate manageable tolerability and encouraging early anti-tumor activity across various PRAME-expressing solid tumors, including ovarian cancer. The dose escalation and determination of the recommended Phase 2 dose (RP2D) are expected to be completed in 2026, with forthcoming data to include outcomes from the two highest dose levels.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001144319-en) on December 11, 2025, and is solely responsible for the information contained therein.